GT Biopharma Inc. (NASDAQ:GTBP) Relative Strength Index (RSI) is 59.15, with weekly volatility at 10.24% and ATR at 1.43. The GTBP stock’s 52-week price range has touched low of $2.04 and a $18.96 high. Intraday shares traded counted 0.48 million, which was 26.04% higher than its 30-day average trading volume of 643.51K. Its shares traded lower over the last trading session, losing -13.98% on 06/03/21. The shares fell to a low of $16.18 before closing at $16.31. GTBP’s previous close was $18.96 while the outstanding shares total 28.39M. The firm has a beta of 0.29.
Investors have identified the Biotechnology company GT Biopharma Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $329.46 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
GT Biopharma Inc. (GTBP) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 27.64 million total, with 3.63 million as their total liabilities.
Potential earnings growth for GT Biopharma Inc. (GTBP)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/17/2021 quarter of the year, GT Biopharma Inc. recorded a total of 29.0 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 96.31% coming in sequential stages and their sales for the 08/17/2021 quarter increasing by 92.45%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent -29.0 million trying to sell their products during the last quarter, with the result yielding a gross income of 0.7 million. This allows shareholders to hold on to 28.39M with the recently reported earning now reading -1.83 cents per share. This is a figure that compared to analyst’s prediction for their 08/17/2021 (-1.83 cents a share).
Having a look at the company’s valuation, the company is expected to record -1.08 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on GTBP sounds very interesting.
Is the stock of GTBP attractive?
In the last 6 months, insiders have changed their ownership in shares of company stock by 1.00%.
3 out of 3 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on GT Biopharma Inc.. 0 analysts has assigned a Sell rating on the GTBP stock. The 12-month mean consensus price target for the company’s shares has been set at $23.67.